Navigation Links
Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients

mber of complete resections in the overall population was three times higher in the Erbitux plus FOLFIRI arm.

“These encouraging results indicate that we have a new first-line treatment option for metastatic colorectal cancer,” said Eric Van Cutsem, MD, PhD, a professor at University Hospital Gasthuisberg in Leuven, Belgium, and lead author of the study. “These findings are remarkable because they point towards the potential for this combination to provide a cure for those patients who were able to undergo a complete resection.”

These results were supported by the findings of the OPUS(b) study. Erbitux plus FOLFOX (oxaliplatin-based therapy) was compared with FOLFOX alone to measure overall response rate (tumor shrinkage by 50% or more). Response rate was found to be 46% in the Erbitux arm compared with 36% in the oxaliplatin-only arm. The safety profile of Erbitux in combination with chemotherapy was manageable and consistent with the current safety information.

Overall, these first-line studies demonstrate that, when added to current standard chemotherapy, Erbitux significantly increases response and resection rates, which in turn, significantly increases the chance of cure for mCRC patients.

In recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) – which is notoriously difficult to treat – first-line Erbitux combined with platinum-based chemotherapy met the primary endpoint of increasing overall survival. This phase III randomized controlled European trial, known as EXTREME(c), studied more than 400 patients treated with Erbitux in combination with either cisplatin- or carboplatin-based therapy compared with patients treated with platinum-based therapy alone. The trial represents a significant breakthrough and the first time in 35 years that a survival benefit has been demonstrated in this group of patients in a randomiz
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
2. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
3. Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
4. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
5. Merck Serono Announces Presentation of Phase III Clinical Data on Safinamide in Parkinson’s Disease at the American Academy of Neurology 59th Annual Meeting
6. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
7. Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:9/2/2014)... 2014 According to a new ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... CAGR of 10.1% from 2014 to 2020. ... are used in the treatment and prevention of various ... other medical disorders. Biological drugs include therapeutic proteins, monoclonal ...
(Date:9/2/2014)... Sept. 2, 2014  For over a decade SafeMinds has ... between vaccines and autism. But at least for one study, ... a statement , William Thompson , Ph.D. acknowledged ... the MMR vaccine to an increased risk of autism in ... same data suggests that African American males have a 340% ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 ... today an increase in capital and cash advance ... Intuitive Surgical System,s da Vinci Robot. With over ... product, Legal-Bay focuses on providing lawsuit cash advances ... injuries, nerve damage, lacerations to internal organs, burns ...
Breaking Medicine Technology:CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 2CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 3CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 4CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 5CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 6CDC vaccine scientist admits wrongdoing. 2CDC vaccine scientist admits wrongdoing. 3da Vinci Lawsuit Settlement Funding Amounts Increased at Legal-Bay Funding 2da Vinci Lawsuit Settlement Funding Amounts Increased at Legal-Bay Funding 3
... Dec. 21, 2011  Shareholders of Medco Health Solutions, Inc. (NYSE: ... Express Scripts. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO ) ... vote present in person or by proxy at a special ... Merger dated July 20, 2011 by a margin of 99 ...
... 2011 Actavis Group, the international generic pharmaceuticals company, today ... a binding letter of intent (LOI) with QRxPharma Limited (ASX: ... United States.  Under the terms of the ... IR, a patented 3:2 ratio fixed dose combination of morphine ...
Cached Medicine Technology:Medco Shareholders Approve Merger With Express Scripts 2Actavis to Launch Novel Pain Medication in the US 2Actavis to Launch Novel Pain Medication in the US 3
(Date:9/2/2014)... N.J. (PRWEB) September 02, 2014 ... technologies and development solutions for drugs, biologics and ... of its strategic partner, Eli Lilly’s growth, it ... packaging lines at its Philadelphia Clinical Supply Center ... syringe packaging capabilities in its clinical supply facility ...
(Date:9/2/2014)... The performance of the Lotteries ... years. Industry revenue is estimated to grow at a ... through 2014-15, following stabilised growth over the past three ... alternate forms of gambling. Horse and sports betting, poker ... all become increasingly popular over the past five years, ...
(Date:9/2/2014)... Based on new studies, concerns ... kidney and spleen surgeries, have continued to mount. ... patients. , An article in the "Public ... Titilope Oduyebo and Bradley J. Quade called, "Peritoneal ... on Nov 26, 2012 defines a morcellator ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- When it comes to excess ... equal, a new study finds. The research found that ... person,s odds for high blood pressure more than overall body ... of high blood pressure. But it wasn,t clear how the ... to researchers at University of Texas Southwestern Medical Center in ...
(Date:9/2/2014)... York (PRWEB) September 02, 2014 ... announces that Class Counsel has filed an application ... awards in the class action litigation brought over ... LLP, the Court-Appointed Class Counsel in this litigation ... Bernstein, LLP; Audet & Partners, LLP; Levin Fishbein, ...
Breaking Medicine News(10 mins):Health News:Catalent Supports Eli Lilly's Growing Global Clinical Trials Needs with New Investment in Automated Packaging Solutions 2Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:New York Law Firm Discusses Allegedly Dangerous Surgical Morcellator Devices And Cancer Risk 2Health News:New York Law Firm Discusses Allegedly Dangerous Surgical Morcellator Devices And Cancer Risk 3Health News:'Spare Tire' May Be Especially Bad for Your Blood Pressure 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 3
... a brain cancer death sentence. It is the most lethal ... are diagnosed with GBM annually in the U.S., half ... within 3 years. The treatments include highly invasive surgeries to ... dose, both leading to a very low quality of life. ...
... conducted by the University of Michigan’s researchers has revealed that those ... unsafe are likely to put on weight. As many as 16% ... in the US are reported to be overweight, while in the ... tripled since the early 1990s. ,The researchers, led ...
... one more reason to raise a toast- a formula for ... // can pep-up your spirits and relish the ... University, and author of the formula for Marks & Spencer, ... open a champagne bottle. According to smith, P = T/4.5 ...
... difficult acrobatic stunts and are paying the price with a ... ,Cheerleaders catapult in the air, climb human ... the ground. They also make it to the emergency room. ... Pediatrics estimates that 208,800 young people aged 5 to 18 ...
... that is mainly present in pain relievers. Recently there is ... // clinicians complaining about over dosage of Acetaminophen. ... 50% of these cases are unintentional. Drugs like Tylenol, Benadryl, ... as one of the main composition in them. ...
... smokers or those who have been smoking in the past have ... tomography (CT scan) to detect // lung cancer if any, ... effective treatment and thereby improve the prognosis. ,The ... family history of the dreadful disease. For those of you ...
Cached Medicine News:Health News:Radiology advance points way to non-invasive brain cancer treatment 2Health News:Surroundings Have An Effect On Weight 2Health News:Cheerleaders run high risk of injury-US study 2Health News:Painkillers Lead To Liver Failure 2Health News:CT Scan A Must For Smokers With Family History Of Lung Cancer 2
... navigation for Spine is ... integrate C-arm fluoroscopy with ... 3500 - spine Multi-application ... for ENT, cranial and ...
The ZEPHIR Anterior Cervical Plate System is the lowest profile plate clinically available....
... Mx8000 is a family of multislice CT ... version, Mx8000 also is available in an ... the same friendly user interface, advanced applications ... Both Dual and Quad systems can be ...
... 16 is Philips premium 16-slice CT scanner. ... to automatically delivering high quality, advanced results, the ... a platform that has been the most popular ... comprehensive organ assessment literally within seconds, and with ...
Medicine Products: